We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Study Shows Varied Results from Different Methods of Measuring Albumin

By LabMedica International staff writers
Posted on 21 Feb 2017
Print article
Image: A structural model of serum albumin (Photo courtesy of Wikimedia Commons).
Image: A structural model of serum albumin (Photo courtesy of Wikimedia Commons).
A recent paper compared the accuracy of several different methods for determining levels of serum or plasma albumin, measurements, which are used to evaluate the nutritional status, kidney function, and fluid balance of dialysis patients.

Investigators at the University of Virginia Health System and Virginia Commonwealth University used 24 testing methods offered by various companies to analyze pools that had been prepared from residual patient serum and heparin plasma from patients without renal disease, and serum from patients with kidney failure before hemodialysis. Albumin was measured in all samples and in ERM-DA470k/IFCC reference material (RM) by three immunochemical, nine bromcresol green (BCG), and 12 bromcresol purple (BCP) methods.

Results revealed that two of three immunochemical procedures, five of nine BCG, and 10 of 12 BCP methods recovered the RM value within its uncertainty. One immunochemical and three BCG methods were biased versus the RM value. Random error components were small for all measurement procedures. Biases for plasma samples were generally higher than for serum samples for all method types. For most measurement procedures, biases were lower for serum from patients on hemodialysis versus patients without kidney disease.

“Nephrologists follow albumin results closely because the results are going to tell them if they need to do anything extra for these patients,” said contributing author Dr. David Bruns, professor of pathology at the University of Virginia Health System. “We know for a fact that this [albumin levels] correlates with mortality. National guidelines define what an acceptable range is and what is not acceptable.”

The investigators concluded that significant differences among immunochemical, BCG, and BCP methods compromised the interpretation of serum albumin results. Therefore, guidelines and calculations for clinical management of kidney and other diseases must consider the method used for albumin measurement until harmonization can be achieved.

The study was published in the January 2017 issue of the journal Clinical Chemistry.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.